Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics Q1 net loss widens
For the first quarter of 2009, the company reported net sales of $12.47 million, compared to $11.49 million for the same quarter in 2008. Ron Cohen, president and
For the first quarter of 2009, the company reported net sales of $12.47 million, compared to $11.49 million for the same quarter in 2008. Ron Cohen, president and
Slater Technology Fund and other previous investors also participated in the round. The proceeds will be used to further develop NABsys’s proprietary DNA sequencing platform. Based on technology
In this new role, Dr Mueller will expand his leadership responsibilities to cover all of Vertex’s global R&D, including clinical and non-clinical development, clinical operations, medical and regulatory
According to Invitrogen, Dynabeads SSEA-4 addresses a key challenge in translational research by separating undifferentiated stem cells from those that are differentiated. Scientists from Invitrogen and the Buck
The expansion is being led by Reiko Nishiguchi, sales director, to provide sales, technology, service and marketing support throughout Asia via a multi-lingual staff. The new office is
Spear is an international, multi-center, randomized, controlled, pivotal Phase III trial of picoplatin in patients with small cell lung cancer (SCLC) who were refractory to or progressed within
The suit, filed in US District Court for the Western District of Wisconsin, asserts that Affymetrix’s GeneChip HT array plate and GeneChip HT array plate scanner infringe upon
According to Merck, launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted. Bioequivalent to the existing Glucophage
“We have a strong pipeline of new products in the FDA, additional new products coming through the development process, such as our troponin assay, but our marketing efforts
As of March 31, 2009, Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) of $40.7 million. “During the first four months